bioRxivCancer BiologyPreprint
A C/ebpα isoform-specific differentiation program in primary myelocytes
Abstract
The transcription factor CCAAT-enhancer binding factor alpha (C/ebp) is a master controller of myeloid differentiation that is expressed as long (p42) and short (p30) isoform. Mutations within the CEBPA gene selectively deleting p42 are frequent in human acute myeloid leukemia. Here we investigated the individual genomics and transcriptomics of p42 and p30. Both proteins bound to identical sites across the genome. For most targets, they induced a highly similar transcriptional response with the exception of a few isoform-specific genes. Amongst those we identified early growth response 1 (Egr1) and tribbles 1 (Trib1) as key targets selectively induced by p42 that are also underrepresented in CEBPA-mutated AML. Egr1 executed a program of myeloid differentiation and growth arrest. Oppositely, Trib1 established a negative feedback loop through activation of Erk1/2 kinase thus placing differentiation under control of signaling. Unexpectedly, differentiation elicited either by removal of an oncogenic input or by G-CSF did not peruse C/ebp as mediator but rather directly affected the cell cycle core by upregulation of p21/p27 inhibitors. This points to functions downstream of C/ebp as intersection point where transforming and differentiation stimuli converge and this finding offers a new perspective for therapeutic intervention.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Arginine methylation of the p30 C/EBPα oncoprotein regulates progenitor proliferation and myeloid differentiation
L. T. Nguyen, K. Zimmermann, … A. Leutz·bioRxiv·Mar 28, 2024
- Cholesterol Biosynthesis is a Targetable Vulnerability of CEBPA-mutant Acute Myeloid Leukemia
Sofie Ulfbeck Schovsbo, Yang Liu, … Bo Torben Porse·bioRxiv·Feb 20, 2026
- MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia
Dorien Pastoors, Marije Havermans, … Ruud Delwel·BloodPeer-reviewed·Oct 8, 2025
- PTPRJ Drives Clonal Selection in CEBPA mutated AML
Alexandra Lubin, Catherine Hockings, … Elspeth M. Payne·bioRxiv·Jul 8, 2026
- CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
Travis J. Fleming, Mateusz Antoszewski, … Vijay G. Sankaran·BloodPeer-reviewed·Sep 24, 2025
- Single-cell multiomics reveals a gene regulatory circuit promoting leukemia cell differentiation